General Assembly Meeting Thursday, May 5th 10:00 – 13:00

General Assembly Meeting - 2022

A virtual (Zoom) and face-to-face meeting in Paris, France

followed by Lunch

Other Logistical information to follow nearer the time




The 2020 GA meeting which normally takes place in May was postponed to November 4th due to the global pandemic. The November 4th meeting which was virtual saw 20 attendees and lasted an hour as most of the GA mandated task/decisions were addressed by way of votes prior to the meeting. Chaired by Interim Chairman Dr Bernd Friede, the meeting though brief was effective with some key decisions taken as follows:

Some highlights:

  • Executive Committee: A new Executive team was endorsed with the 2nd Vice-Chairman becoming the Chairman and Secretary General maintained to ensure continuity
  • Non-EU letter of Access Fees: Letter of Access fees and administration fees for non-EU REACH-Like regulations per substance, per legal entity for non-MARA members was established
  • Members involvement in Non-EU regulations: MARA members wishing to register substances in non-EU REACH-like regulations will only pay administration fees as they own the data generated by MARA
  • Technical update: Three dossiers updated this year lead to a new classification for manganese based UVCB’s
  • 2020 Workplan and budget were ratified in Q1, 2020 via round robin votes.

Trimanganese tetraoxide (EC :215-266-5; Cas :1317-35-7)

The lead dossier was submitted in 2010 with no testing proposals. In July 2013 a compliance check was initiated, requesting more details with regard to the following information requirements/updates:

  • Annex IX 8.7.2 (pre-natal developmental study, oral route, OECD 414)
  • Annex X, 8.7.3 (two-generation reproductive toxicity study, oral route, OECD 416 or an extended one generation reproductive toxicity study, OECD 443)

By 27 September 2013 the consortium secretariat on behalf of the lead registrant had responded to the ECHA’s draft decision concerns, highlighting the lack of need for such animal-intensive studies and encouraging the use of already available data within the manganese data pool.

In July 2016 ECHA notified the competent authorities of the member states of its draft decision together with the registrant's comments. No member state commented on the draft decision. A final decision requesting the following study was published in September 2016:

  • Pre-natal developmental toxicity study (Annex IX, 8.7.2.; test method: EU B.31/OECD 414) in rats or rabbits, oral route - while a decision was not yet reached on the two-generation reproductive toxicity study endpoint, 

The Annex IX 8.7.2 (pre-natal developmental study, oral route, OECD 414) study, now completed (May 10, 2018) revealed several fetal effects. Litter size and mean fetal weights were slightly reduced. Embryo-fetal survival was considered unaffected by treatment, but fetal development was adversely affected with bent scapula(e); bent radius/ulna/fibula; short/bent/and thickened humerus with associated medially thickened/kinked/incompletely ossified ribs.

Therefore, the No-Observed- Effect-Level (NOEL) for maternal toxicity was 750 mg/kg/day and the No-Observed-Adverse-Effect-Level (NOAEL) for embryo-fetal toxicity was concluded to be 250 mg/kg/day.

The updated dossier was submitted earlier this year (Q1, 2019) with new available data from ECHA's compliance checks request, new uses and a new CLP classification. All co-registrants that had met their financial obligations were provided with the following:

1) Updated CSR

2) Exposure scenarios for their eSDS

3) Updated CLP classification.

This dossier has undergone significant amount of work post this year's  Q1 submission. In the end, ECHA accepted  the Pre-natal developmental toxicity study (Annex IX, 8.7.2.; test method: EU B.31/OECD 414) in rat, oral route study.  However, in Q3 another letter from ECHA requested that several ecotoxicology endpoints  be reveiwed  or a corresponding study be carried out.  To this end a dossier update is anticipated by end of year - 2019.

Note: Post 2018, the consortium will no longer invoice co-registrants  for ECHA requested studies retrospectively. All compliance check related work will require co-registrants to contribute their share before any dossier update work can begin. 

« Back to news

About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)